Map of spinal cord formation gives new knowledge on diseases of … – EurekAlert

Researchers at Karolinska Institutet in Sweden have mapped how cells in the human spinal cord are formed in the embryo and what genes control the process. Their findings can give rise to new knowledge on how injury to and diseases of the spinal cord arise and how they can be treated. The study has been published in the journal Nature Neuroscience.

The spinal cord is part of the central nervous system, serving as an important bridge for communication between the brain and the rest of the body. There are many different types of cells in the human spinal cord but much still remains to be understood about how these cells are formed from stem cells during embryonic development.

Many neurodegenerative diseases and injuries of the spinal cord are incurable because of the poor regeneration of human spinal cord cells, says the studys first author Xiaofei Li, assistant professor at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet. A better grasp of how the spinal cord is formed and how different genes control this development can lead to new therapies for spinal cord injuries and diseases such as ALS or cancer of the nervous system.

User-friendly online tool

The researchers have built up an extensive map of all the cell types of the human spinal cord, showing where the cells are and what genes they express during embryonic development. The information has been gathered in a user-friendly interactive online tool that researchers or other interested parties can use to search for genes that shape how the spinal cord develops.

The study identified key genes that affect how the stem cells migrate when the spinal cord is formed and what specialisations they have. A comparison with spinal cord development in mice revealed important differences between mice and humans.

These findings are very important because much of what we already know is based on mouse studies, says Dr Li.

The study was conducted using single-cell RNA sequencing and spatial transcriptomics, which enabled the researchers to map thousands of genes in each individual cell and analyse how they are expressed at different sites of the same tissue section.

Learning more about child cancer

The researchers also studied an unusual tumour type called ependymoma, which manifests as malignant brain tumours in children or benign spinal cord tumours in adults. On identifying genes that are specific to tumour development they were thus able to demonstrate how their findings can be used to increase understanding of diseases of the nervous system.

Well now be interrogating how stem cells form different cell types and change their properties both during embryonic development and later during maturity and ageing, as well as in different kinds of pathological conditions, says the studys last author Erik Sundstrm, senior researcher at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet.

The study was financed by the Erling Persson Foundation, the Knut and Alice Wallenberg Foundation, Karolinska Institutet and SciLifeLab. Co-authors Zaneta Andrusivova, Ludvig Larsson and Joakim Lundeberg are consultants at 10x Genomics Inc., for which Mats Nilsson is also an advisor.

Publication: Profiling spatiotemporal gene expression of the developing human spinal cord and implications for ependymoma origin. Xiaofei Li, Zaneta Andrusivova, Paulo Czarnewski, Christoffer Mattsson Langseth, Alma Andersson, Yang Liu, Daniel Gyllborg, Emelie Braun, Ludvig Larsson, Lijuan Hu, Zhanna Alekseenko, Hower Lee, Christophe Avenel, Helena Kopp Kallner, Elisabet kesson, Igor Adameyko, Mats Nilsson, Sten Linnarsson, Joakim Lundeberg, Erik Sundstrm. Nature Neuroscience, online 24 April 2023, doi: 10.1038/s41593-023-01312-9.

Nature Neuroscience

Experimental study

Human tissue samples

Profiling spatiotemporal gene expression of the developing human spinal cord and implications for ependymoma origin

24-Apr-2023

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original post:
Map of spinal cord formation gives new knowledge on diseases of ... - EurekAlert

Cell Therapy Market to Witness Rapid Growth, Driven by Growing Applications in Oncology and Regenerative Medic – openPR

Global Cell Therapy Market report from Global Insight Services is the single authoritative source of intelligence on Cell Therapy Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.

To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS21212

Cell therapy is a type of treatment that uses living cells to treat a disease or condition. The cells can be from the patient's own body, or they can be from a donor. Cell therapy is also called cellular therapy, cell transplantation, or regenerative medicine.

Key Trends:

The major factors driving the growth of this market are the increasing prevalence of cancer and chronic diseases, and the growing demand for personalized medicine.

However, the high cost of cell therapy treatments and the lack of skilled professionals are the major factors restraining the growth of this market.

Read more about Cell Therapy Market here: https://www.globalinsightservices.com/reports/cell-therapy-market

Key Drivers:

The key drivers of the cell therapy market are the increasing incidence of cancer, the rise in the aging population, and the growing demand for minimally invasive treatments.

The aging population is also a major driver of the cell therapy market, as the risk of developing cancer increases with age.

The demand for minimally invasive treatments is also growing, as patients seek to avoid the side effects of traditional cancer treatments such as chemotherapy and radiation therapy.

Get Customized Report as Per Your Requirement: https://www.globalinsightservices.com/request-customization/GIS21212

Market Segments:

The cell therapy market is segmented by therapy type, therapeutic area, end-user, and region. By therapy type, the market is classified into autologous, and allogenic. On the basis of therapeutic area, it is bifurcated into malignancies, autoimmune disorders, dermatology, and others. Based on end-use, it is divided into hospitals, clinics, academic, and others. Region-wise, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World.

Key Players:

The global cell therapy market includes players such as Allosource, Cells for Cells, Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co Ltd, Kolon Tissuegene Inc, Medipost Co Ltd, Mesoblast Ltd, Nuvasive Inc, Osiris Therapeutics, Inc, Stemedica Cell Technologies Inc, and others.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS21212

Contact Us:

Global Insight Services LLC16192, Coastal Highway, Lewes DE 19958E-mail: info@globalinsightservices.comPhone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

View original post here:
Cell Therapy Market to Witness Rapid Growth, Driven by Growing Applications in Oncology and Regenerative Medic - openPR

The first babies conceived with a sperm-injecting robot have been born – MIT Technology Review

I was calm. In that exact moment, I thought, Its just one more experiment, says Eduard Alba, the student mechanical engineer who commanded the sperm-injecting device.

The startup company that developed the robot, Overture Life, says its device is an initial step toward automating in vitro fertilization, or IVF, and potentially making the procedure less expensive and far more common than it is today.

Right now, IVF labs are staffed by trained embryologists who earn upwards of $125,000 a year to delicately handle sperm and eggs using ultra-thin hollow needles under a microscope.

But some startups say the entire process could be carried out automatically, or nearly so. Overture, for instance, has filed a patent application describing a biochip for an IVF lab in miniature, complete with hidden reservoirs containing growth fluids, and tiny channels for sperm to wiggle through.

Think of a box where sperm and eggs go in, and an embryo comes out five days later, says Santiago Munn, the prize-winning geneticist who is chief innovation officer at the Spanish company. He believes that if IVF could be carried out inside a desktop instrument, patients might never need to visit a specialized clinic, where a single attempt at getting pregnant can cost $20,000 in the US. Instead, he says, a patients eggs might be fed directly into an automated fertility system at a gynecologists office. It has to be cheaper. And if any doctor could do it, it would be, says Munn.

MIT Technology Review identified a half-dozen startups with similar aims, with names like AutoIVF, IVF 2.0, Conceivable Life Sciences, and Fertilis. Some have roots in university laboratories specializing in miniaturized lab-on-a-chip technology.

So far, Overture has raised the most: about $37 million from investors including Khosla Ventures and Susan Wojcicki, the former CEO of YouTube.

The main goal of automating IVF, say entrepreneurs, is simple: its to make a lot more babies. About 500,000 children are born through IVF globally each year, but most people who need help having kids dont have access to fertility medicine or cant pay for it.

How do we go from half a million babies a year to 30 million? wonders David Sable, a former fertility doctor who now runs an investment fund. You cant if you run each lab like a bespoke, artisanal kitchen, and that is the challenge facing IVF. Its been 40 years of outstanding science and really mediocre systems engineering.

While an all-in-one fertility machine doesnt yet exist, even automating parts of the process, like injecting sperm, freezing eggs, or nurturing embryos, could make IVF less expensive and eventually support more radical innovations, like gene editing or even artificial wombs.

But it wont be easy to fully automate IVF. Just imagine trying to make a robot dentist. Test-tube conception involves a dozen procedures, and Overtures robot so far performs only one of them, and only partially.https://wp.technologyreview.com/wp-content/uploads/2023/04/robot-procedure-notext.mp4An video showing robotic fertilization of an egg at Overture Life Sciences. A vibrating needle pierces the egg, depositing a single sperm cell.

OVERTURE

The concept is extraordinary, but this is a baby step, says Gianpiero Palermo, a fertility doctor at Weill Cornell Medical Center who is credited with developing the fertilization procedure known as intracytoplasmic sperm injection, or ICSI, in the 1990s. Palermo notes that Overtures researchers still relied on some manual assistance for tasks like loading a sperm cell into the injector needle. This is not yet robotic ICSI, in my opinion, he says.

Other doctors are skeptical that robots can, or should, replace embryologists anytime soon. You pick up a sperm, put it in an egg with minimal trauma, as delicately as possible, says Zev Williams, director of Columbia Universitys fertility clinic. For now, humans are far better than a machine, he says.

His center did develop a robot, but it has a more limited aim: dispensing tiny droplets of growth medium for embryos to grow in. Its not good for the embryos if the drop size differs, says Williams. Creating the same drops over and over againthat is where the robot can shine. He calls it a low risk way to introduce automation to the lab.

One obstacle to automating conception is that so-called microfluidicsanother name for lab-on-a-chip technologyhasnt lived up to its hype.

Jeremy Thompson, an embryologist based in Adelaide, Australia, says hes spent his career figuring out how to make the lives of embryos better as they grow in laboratories. But until recently, he says, his tinkering with microfluidic systems yielded an unambiguous result: Bollocks. It didnt work. Thompson says IVF remains a manual process in part because no one wants to trust an embryoa potential personto a microdevice where it could get trapped or harmed by something as tiny as an air bubble.

A few years ago, though, Thompson saw images of a minuscule Eiffel Tower, just one millimeter tall. It had been made using a new type of additive 3D printing, in which light beams are aimed to harden liquid polymers. He decided this was the needed breakthrough, because it would let him build a box or a cage around an embryo.

Since then, a startup he founded, Fertilis, has raised a couple of million dollars to print what it calls see-through pods or micro-cradles. The idea is that once an egg is plopped into one, it can be handled more easily and connected to other devices, such as pumps to add solutions in minute quantities.

Inside one of Fertiliss pods, an egg sits in a chamber no larger than a bead of mist, but the container itself is large enough to pick up with small tongs. Fertilis has published papers showing it can flash-freeze eggs inside the cradles and fertilize them there, too, by pushing in a sperm with a needle.

A human egg is about 0.1 millimeters across, at the limit of what a human eye can see unaided. Right now, to move one, an embryologist will slurp it up into a hollow needle and squirt it out again. But Thompson says that once inside the companys cradles, eggs can be fertilized and grow into embryos, moving through the stations of a robotic lab as if on a conveyor belt. Our whole story is minimizing stress to embryos and eggs, he says.

Thompson hopes someday, when doctors collect eggs from a womans ovaries, theyll be deposited directly into a micro-cradle and, from there, be nannied by robots until theyre healthy embryos. Thats my vision, he says.https://wp.technologyreview.com/wp-content/uploads/2023/04/better-injection.mp4A video taken through a microscope shows a microneedle penetrating eggs held in 3D-printed pods, or cradles. An egg is about 0.1 mm across.

FERTILIS

MIT Technology Review found one company, AutoIVF, a spinout from a Massachusetts General HospitalHarvard University microfluidics lab, that has won more than $4 million in federal grants to develop such an egg-collecting system. It calls the technology OvaReady.

Egg collection happens after a patient is treated with fertility hormones. Then a doctor uses a vacuum-powered probe to hoover up eggs that have ripened in the ovaries. Since theyre floating in liquid debris and encased in protective tissue, an embryologist needs to manually find each one and denude it by gently cleaning it with a glass straw.

An AutoIVF executive, Emre Ozkumur, declined to discuss the projectthe company wants to stay under the radar a little bit longer, he saysbut its grant and patent documents suggest it is testing a device that can spot and isolate eggs and then automatically strip them of surrounding tissue, perhaps by swishing them through something that resembles a microscopic cheese grater.

Once an egg is in hand, doctors need to match it with a sperm cell. To help them pick the right one, Alejandro Chavez-Badiola, a fertility doctor based in Mexico, started a company, IVF 2.0, that developed software to rank and analyze sperm swimming in a dish. Its similar to computer-vision programs that track sports players as they run, collide, and switch directions on a pitch.

The job is to identify healthy sperm by assessing their shape and seeing how well they swim. Motility, says Chavez-Badiola, is the ultimate expression of sperm health and normality. While a person can only keep an eye on a few sperm at one time, a computer doesnt face that limit. We humans are good at channeling our attention to a single point. We can assess five or 10 sperm, but you cant do 50, says Chavez-Badiola.

His IVF clinic is running a head-to-head study of human- and computer-picked sperm, to see which lead to more babies. So far, the computer holds a small edge.

We dont claim its better than a human, but we do claim its just as good. And it never gets tired. A human has to be good at 8 a.m., after coffee, after having an argument on the phone, he says.

Chavez-Badiola says such software will be the brains to command future automated labs. This year, he sold the rights to use his sperm-tracking program to Conceivable Life Sciences, another IVF automation startup being formed in New York where Chavez-Badiola will act as chief product officer. Also joining the company is Jacques Cohen, a celebrated embryologist who once worked at the British clinic where the first IVF baby was born in 1978.https://wp.technologyreview.com/wp-content/uploads/2023/04/Conceivable-720.mp4A computer system developed by IVF 2.0 tracks and grades sperm as they swim, using image-recognition software.

CONCEIVABLE

Conceivable plans to create an autonomous robotic workstation that can fertilize eggs and cultivate embryos, and it hopes to demonstrate all the key steps this year. But Cohen allows that automation could take a while to become reality. It will happen step by step, he says. Even things that seem obvious take 10 years to catch on, and 20 to become routine.

The investors behind Conceivable think they can cash in by expanding the use of IVF. Its nearly certain that the IVF industry could grow to five or 10 times its current size. In the US, fewer than 2% of kids are born this way, but in Denmark, where the procedure is free and encouraged, the figure is near 10%.

That is the true demand, says Alan Murray, an entrepreneur with a background in software and co-working spaces who cofounded Conceivable with his business partner, Joshua Abram. The challenge is that these wonderful rich and eccentric countries can do it, but the rest of the world cannot. But they have demonstrated the true human need, he says. What they have done with money, we need to do with technology.

Murray estimates the average IVF baby in the US costs $83,000 if you include failed attempts, which are common. He says his companys objective is to lower the cost by 70%, something he says can happen if success rates increase.

But its not a given that robots will reduce the cost of IVF or that any savings will be passed on to patients. Rita Vassena, an advisor to Conceivable and CEO at Fecundis, a fertility science company, says the field has a history of introducing innovations without appreciably increasing pregnancy rates. The trend [is] toward piling up tests and technologies rather than a true effort to lower access barriers, she says.

Last fall, the researchers at Overture and doctors at New Hope published a description of their work with the robot, claiming that two patients had become pregnant. That was done after gaining ethics approval for the study, says John Zhang, founder of New Hope and senior author of the report.

Both those children have now been born, says Jenny Lu, the egg donation coordinator at New Hope. MIT Technology Review was able to speak to the father of one of the children.

Its wild, isnt it, said the father, who asked to remain anonymous. They said up until now it had always been done manually.

He said he and his partner had tried IVF several times before, without success. Both cases of robot injection involved donor eggs, which were provided to the patients for free (they can cost $15,000 otherwise). In each case, after being fertilized and grown into embryos, they were implanted in the uterus of the patient.

Donor eggs are most often used when a patient is older, in her 40s, and cant get pregnant otherwise.

Since automation wont directly solve the problem of aging eggs, an IVF lab-in-a-box wont fix this intractable reason that fertility treatments fail. However, automation could let doctors begin precisely measuring what they do, allowing them to fine-tune their procedures. Even a small increase in success rates could mean tens of thousands of extra babies every year.

Kathleen Miller, chief scientist of Innovation Fertility, a chain of clinics in the southern US, says her centers are now using computer-vision systems to study time-lapse videos of growing embryos and trying to see if any data explain why some become babies and others dont. Were putting it into models, and the question is Tell me something I dont know, she says.

Were going to see an evolution of what an embryologist is, Miller predicts. Right now, they are technicians, but theyre going to be data scientists.

For some proponents of IVF automation, an even wilder future awaits. By giving over conception to machines, automation could speed the introduction of still-controversial techniques such as genome editing, or advanced methods of creating eggs from stem cells.

Although Munn says Overture Life has no plans to modify the genetic makeup of children, he allows it would be a simple matter to use the sperm-injecting robot for that purpose, since it could dispense precise amounts of gene-editing chemicals into an egg. It should be very easy to add to the machine, he says.

Even more speculative technology is on the horizon. Fertility machines could gradually evolve into artificial wombs, with children gestated in scientific centers until birth. I do believe we are going to get there, says Thompson. There is credible evidence that what we thought was impossible is not so impossible.

Others imagine that robots could eventually be shot into outer space, stocked with eggs and sperm held in a glassy state of stasis. After a thousand-year journey to a distant planet, such machines might boot up and create a new society of humans.

Its all part of the goal of creating more people, and not just here on Earth. There are people thinking that humankind should be an interplanetary species, and human lifetimes are not going to be enough to reach out to these worlds, says Chavez-Badiola. Part of the job of a scientist is to keep dreaming.

More:
The first babies conceived with a sperm-injecting robot have been born - MIT Technology Review

Loss of autism-linked gene dampens social interactions in animals – Spectrum – Autism Research News

Stranger danger: Unlike wildtype mice (top row), those lacking GIGYF1 (bottom row) avoid unfamiliar mice (right) in favor of those they know (left), position heat maps show.

Mice and zebrafish that lack the autism-linked gene GIGYF1 show atypical social behaviors, according to a new study. The findings tie variations in the gene to social traits in autistic people, the researchers say.

Among the genes strongly linked to autism, GIGYF1 ranks as the second most commonly mutated one in people with autism and related neurodevelopmental conditions. But little is known about the genes contribution to autism traits, says Bo Xiong, professor of forensic medicine at Huazhong University of Science and Technology in China. Initial findings point to a role in regulating social behavior: Deleting the gene blunts social memory in mice, through mechanisms thought to be mediated by impaired insulin signaling.

GIGYF1 is also implicated in other pathways including autophagy and mRNA regulation that are often altered in people with neurodevelopmental conditions, says Jeremy Veenstra-VanderWeele, professor of developmental psychiatry at Columbia University, who was not involved in the study. But it had not previously been rigorously studied for its impact on neurodevelopment and downstream behavior, he says.

Xiong and his colleagues combed sequencing data from SPARK, a project that aims to collect genetic and clinical information from 50,000 families that have at least one child with autism. (SPARK is funded by the Simons Foundation, Spectrums parent organization).

They identified seven new GIGYF1 mutations and pooled the data with 19 previously reported variants. Cross-referencing with clinical information revealed that 86 percent of people with GIGYF1 mutations have autism. A similar proportion have communication difficulties and social phobia, alongside sleep problems and delayed speech.

Zebrafish embryos edited via CRISPR to lack GIGYF1 develop more slowly than their wildtype counterparts, Xiong and his colleagues found. As adults, the fish are more anxious and less willing to socialize.

Zebrafish are typically highly sociable: They rarely swim alone, preferring to travel in clusters called shoals. When placed in a three-chambered enclosure with a fish at one end and an empty chamber at the other, wildtype fish will opt for company. But fish lacking GIGYF1 prefer solitude and appear anxious, frequently darting around the tank. Whats more, they form looser shoals, maintaining more distance between themselves and others.

Mice engineered to express just one copy of the GIGYF1 gene also display social deficits. When the researchers tested for social novelty a mouses inclination to investigate a stranger over those it already knows the mutant mice stayed near the familiar mouse. GIGYF1 deletion also triggered repetitive behaviors, one of the core traits of autism.

The study plays to the strengths of each model, says Julia Dallman, associate professor of biology at the University of Miami in Florida, who was not involved in the study. For example, delayed embryogenesis is easier to spot in zebrafish, which develop outside their mothers body, than in mice. These different models can provide complementary windows of insight into gene function, she says.

But the fish could be tweaked to better reflect the genetics of autism, says Dallman. The study used zebrafish lacking both copies of GIGYF1, but people with the condition have one mutated copy and one functional copy.

Disrupting both gene copies is a good way to understand the biological importance of GIGYF1 but does not model the human condition, Veenstra-VanderWeele agrees.

Mice missing a copy of the gene in only their excitatory neurons still showed repetitive behaviors and impairments in social novelty. Yet deleting a copy of GIGYF1 in only inhibitory neurons triggered a different set of traits, including heightened anxiety and poorer cognition, suggesting that GIGYF1 plays distinct roles in different cell types.

The findings were published 14 March in Biological Psychiatry.

Exactly how GIGYF1 variants cause changes in social behavior remains an open question. Right now, we only know a small piece of the whole picture. We still dont know the exact molecular mechanisms by which these mutations cause behavioral defects, Xiong says.

Initial findings hint at changes in neuronal communication. By screening for transcripts and proteins that bind to GIGYF1, the researchers identified hundreds of downstream targets, including several involved in synaptic transmission. They are now harnessing electrophysiology to see how GIGYF1 deletion in mice influences neuronal chatter.

Because GIGYF1s function appears to be conserved among animal models, it would be interesting to see whether similar effects are seen in organoids and stem cells, says Ctia Igreja, a researcher at the Max Planck Institute for Biology in Tbingen, Germany, who was not involved in the study. If so, scientists may be able to pinpoint the GIGYF1s molecular mechanisms and identify potential therapeutic interventions that alleviate GIGYF1 deficiency, she adds.

Cite this article: https://doi.org/10.53053/GPMX9020

Go here to read the rest:
Loss of autism-linked gene dampens social interactions in animals - Spectrum - Autism Research News

A burst of genomic innovation at the origin of placental mammals … – Nature.com

Lynch, V. J. et al. Ancient transposable elements transformed the uterine regulatory landscape and transcriptome during the evolution of mammalian pregnancy. Cell Rep. 10, 551561 (2015).

Article CAS PubMed PubMed Central Google Scholar

Kin, K. et al. The transcriptomic evolution of mammalian pregnancy: gene expression innovations in endometrial stromal fibroblasts. Genome Biol. Evol. 8, 24592473 (2016).

Article CAS PubMed PubMed Central Google Scholar

Wagner, G. P. Evolutionary innovations and novelties: let us get down to business! Zool. Anz. 256, 7581 (2015).

Article Google Scholar

Hertel, J. et al. The expansion of the metazoan microRNA repertoire. BMC Genom. 7, 25 (2006).

Article Google Scholar

Prochnik, S. E., Rokhsar, D. S. & Aboobaker, A. A. Evidence for a microRNA expansion in the bilaterian ancestor. Dev. Genes Evol. 217, 7377 (2007).

Article CAS PubMed Google Scholar

Grimson, A. et al. The early origins of microRNAs and Piwi-interacting RNAs in animals. Nature 455, https://doi.org/10.1038/nature07415 (2008).

Keniry, A. et al. The H19 lincRNA is a developmental reservoir of miR-675 which suppresses growth and Igf1r. Nat. Cell Biol. 14, 659665 (2012).

Article CAS PubMed PubMed Central Google Scholar

Munaut, C. et al. Dysregulated circulating miRNAs in preeclampsia. Biomed. Rep. 5, 686692 (2016).

Article CAS PubMed PubMed Central Google Scholar

Bastian, F. et al. MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res. 48, 1 (2020).

Google Scholar

Bastian, F. et al. A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome. Annu. Rev. Genet. 49, 213242 (2015).

Article Google Scholar

Ito, M. et al. A trans-homologue interaction between reciprocally imprinted miR-127 and Rtl1 regulates placenta development. Development 142, 24252430 (2015).

CAS PubMed PubMed Central Google Scholar

Farrokhnia, F., Aplin, J. D., Westwood, M. & Forbes, K. MicroRNA regulation of mitogenic signaling networks in the human placenta. J. Biol. Chem. 289, 3040430416 (2014).

Article CAS PubMed PubMed Central Google Scholar

Luo, L. et al. MicroRNA-378a-5p promotes trophoblast cell survival, migration and invasion by targeting Nodal. J. Cell Sci. 125, 3124 LP3132 (2012).

Google Scholar

Morales-Prieto, D. M. et al. MicroRNA expression profiles of trophoblastic cells. Placenta 33, 725734 (2012).

Article CAS PubMed Google Scholar

Tochigi, H. et al. Loss of miR-542-3p enhances IGFBP-1 expression in decidualizing human endometrial stromal cells. Sci. Rep. 7, 40001 (2017).

Article CAS PubMed PubMed Central Google Scholar

Fu, G., Brki, J., Hayder, H. & Peng, C. MicroRNAs in human placental development and pregnancy complications. Int. J. Mol. Sci. 14, 55195544 (2013).

Article CAS PubMed PubMed Central Google Scholar

Harapan, H. & Andalas, M. The role of microRNAs in the proliferation, differentiation, invasion, and apoptosis of trophoblasts during the occurrence of preeclampsiaa systematic review. Tzu Chi Med. J. 27, 5464 (2015).

Article Google Scholar

Hosseini, M. K., Gunel, T., Gumusoglu, E., Benian, A. & Aydinli, K. MicroRNA expression profiling in placenta and maternal plasma in early pregnancy loss. Mol. Med. Rep. 17, 49414952 (2018).

CAS PubMed PubMed Central Google Scholar

Rahman, M. L. et al. Regulation of birthweight by placenta-derived miRNAs: evidence from an arsenic-exposed birth cohort in Bangladesh. Epigenetics 13, 573590 (2018).

Article PubMed PubMed Central Google Scholar

do Imperio, G. E. et al. Chorioamnionitis induces a specific signature of placental ABC transporters associated with an increase of miR-331-5p in the human preterm placenta. Cell. Physiol. Biochem. 45, 591604 (2018).

Article PubMed Google Scholar

Fallen, S. et al. Extracellular vesicle RNAs reflect placenta dysfunction and are a biomarker source for preterm labour. J. Cell. Mol. Med. 22, 27602773 (2018).

Article CAS PubMed PubMed Central Google Scholar

Suwen, C., Liping, S. & Guijiao, F. SP1-mediated long noncoding RNA POU3F3 accelerates the cervical cancer through miR-127-5p/FOXD1. Biomed. Pharmacother. 117, 109133 (2019).

Wang, D., Tang, L., Wu, H., Wang, K. & Gu, D. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma. IUBMB Life 70, 411419 (2018).

Ferri, C. et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. J. Exp. Clin. Cancer Res. 41, 20 (2022).

Article CAS PubMed PubMed Central Google Scholar

Liu, Q., Yan, S., Yuan, Y., Ji, S. & Guo, L. miR-28-5p improved carotid artery stenosis by regulating vascular smooth muscle cell proliferation and migration. Vascular 30, 764770 (2021).

Sheng, C. et al. MiR-340 promotes the proliferation of vascular smooth muscle cells by targeting von HippelLindau tumor suppressor gene. J. Cardiovasc. Pharmacol. 77, 875884 (2021).

Kuang, M. J. et al. CircUSP45 inhibited osteogenesis in glucocorticoid-induced osteonecrosis of femoral head by sponging miR-127-5p through PTEN/AKT signal pathway: experimental studies. Biochem. Biophys. Res. Commun. 509, 255261 (2019).

Farre-Garros, R. et al. Quadriceps miR-542-3p and -5p are elevated in COPD and reduce function by inhibiting ribosomal and protein synthesis. J. Appl. Physiol. 126, 15141524 (2019).

Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, 138 (2015).

Article Google Scholar

Esnault, C., Cornelis, G., Heidmann, O. & Heidmann, T. Differential evolutionary fate of an ancestral primate endogenous retrovirus envelope gene, the EnvV Syncytin, captured for a function in placentation. PLoS Genet. 9, e1003400 (2013).

Article CAS PubMed PubMed Central Google Scholar

Dunwell, T. L., Paps, J. & Holland, P. W. H. Novel and divergent genes in the evolution of placental mammals. Proc. Biol. Sci. 284, 20171357 (2017).

PubMed PubMed Central Google Scholar

Than, N. G. et al. A primate subfamily of galectins expressed at the maternalfetal interface that promote immune cell death. Proc. Natl Acad. Sci. USA 106, 9731 LP9739736 (2009).

Article Google Scholar

Yates, A. et al. Ensembl 2016. Nucleic Acids Res. 44, D710D716 (2016).

Article CAS PubMed Google Scholar

Hauguel-de Mouzon, S. & Guerre-Millo, M. The placenta cytokine network and inflammatory signals. Placenta 27, 794798 (2006).

Article CAS PubMed Google Scholar

Woods, L., Perez-Garcia, V. & Hemberger, M. Regulation of placental development and its impact on fetal growthnew insights from mouse models. Front. Endocrinol. 9, 570 (2018).

Article Google Scholar

Gal, H. et al. Molecular pathways of senescence regulate placental structure and function. EMBO J. 38, e100849e100849 (2019).

Article PubMed PubMed Central Google Scholar

Lynch, V. J., Leclerc, R. D., May, G. & Wagner, G. P. Transposon-mediated rewiring of gene regulatory networks contributed to the evolution of pregnancy in mammals. Nat. Genet. 43, 11541159 (2011).

Article CAS PubMed Google Scholar

Tian, X. et al. Evolution of telomere maintenance and tumour suppressor mechanisms across mammals. Philos. Trans. R. Soc. B Biol. Sci. 373, 20160443 (2018).

Article Google Scholar

McNab, B. K. An analysis of the factors that influence the level and scaling of mammalian BMR. Comp. Biochem. Physiol. Part A 151, 528 (2008).

Article Google Scholar

Garratt, M., Gaillard, J.-M. J., Brooks, R. C. P., Lemaitre, J.-F. & Lematre, J.-F. Diversification of the eutherian placenta is associated with changes in the pace of life. Proc. Natl Acad. Sci. USA 110, 77607765 (2013).

Article CAS PubMed PubMed Central Google Scholar

Welch, J. J., Bininda-Emonds, O. R. P. & Bromham, L. Correlates of substitution rate variation in mammalian protein-coding sequences. BMC Evol. Biol. 8, 53 (2008).

Article PubMed PubMed Central Google Scholar

Spencer, T. E. & Bazer, F. W. Temporal and spatial alterations in uterine estrogen receptor and progesterone receptor gene expression during the estrous cycle and early pregnancy in the Ewe1. Biol. Reprod. 53, 15271543 (1995).

Article CAS PubMed Google Scholar

Godkin, J. D., Bazer, F. W., Moffatt, J., Sessions, F. & Roberts, R. M. Purification and properties of a major, low molecular weight protein released by the trophoblast of sheep blastocysts at Day 1321. Reproduction 65, 141150 (1982).

Article CAS Google Scholar

Morgan, F. J. & Canfield, R. E. Nature of the subunits of human chorionic gonadotropin. Endocrinology 88, 10451053 (1971).

Article CAS PubMed Google Scholar

Tinning, H. et al. The role of CAPG in molecular communication between the embryo and the uterine endometrium: Is its function conserved in species with different implantation strategies? FASEB J. 34, 1101511029 (2020).

Article CAS PubMed Google Scholar

Forde, N. et al. Conceptus-induced changes in the endometrial transcriptome: how soon does the cow know she is pregnant?1. Biol. Reprod. 85, 144156 (2011).

Article CAS PubMed Google Scholar

Morgan, C. C. et al. Heterogeneous models place the root of the placental mammal phylogeny. Mol. Biol. Evol. 30, 21452156 (2013).

Article CAS PubMed PubMed Central Google Scholar

Tarver, J. E. et al. The interrelationships of placental mammals and the limits of phylogenetic inference. Genome Biol. Evol. 8, 330344 (2016).

Article CAS PubMed PubMed Central Google Scholar

Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403410 (1990).

Article CAS PubMed Google Scholar

Giribet, G. TNT: tree analysis using new technology. Syst. Biol. 54, 176178 (2005).

Article Google Scholar

Bartel, D. P. MicroRNA target recognition and regulatory functions. Cell 136, 215233 (2009).

Article CAS PubMed PubMed Central Google Scholar

Mi, H., Muruganujan, A., Ebert, D., Huang, X. & Thomas, P. D. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 47, D419D426 (2019).

Article CAS PubMed Google Scholar

Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 44, D481D487 (2016).

Article CAS PubMed Google Scholar

Anisimova, M. & Yang, Z. Multiple hypothesis testing to detect lineages under positive selection that affects only a few sites. Mol. Biol. Evol. 24, 12191228 (2007).

See the original post:
A burst of genomic innovation at the origin of placental mammals ... - Nature.com

expert reaction to study looking at creating embryo-like structures … – Science Media Centre

April 6, 2023

A study published in Cell Stem Cell looks at the generation of embryo-like structures from monkey embryonic stem cells.

Prof Magdalena Zernicka-Goetz, Bren Professor of Biology and Biological Engineering, California Institute of Technology; and Professor of Mammalian Development and Stem Cell Biology, University of Cambridge, said:

This is an exciting development building on work from our own and other labs showing the importance of establishing interactions between embryonic and extra-embryonic stem cells to establish models of the mammalian embryo at pre-and early post-implantation stages. The excitement of this study is not only that embryos generated from monkey stem cells provide a close model for human embryos, but monkeys are also experimentally tractable.

The authors follow approaches that have been previously used to direct embryonic stem cells into a naive state, and then use treatments that allow the nave monkey ES cells to form extra-embryonic cell types. Together these cells assemble into blastoids, structures resembling blastocysts, that are able to develop in vitro into structures with a striking resemblance to the embryonic disc at gastrulation, both in morphology and gene expression. The blastoids also appear to implant into foster monkey mothers but, in common with similar structures in the mouse, development appears restricted.

This study is a hugely encouraging development in the study of primate embryo models.

The paper is excellent and an important step forward but still the stem cell derived embryos have a limited developmental potential, as the authors state themselves. Nevertheless, it is an important step in the very exciting field of enormous potential for understanding how the embryo develops and why so many pregnancies fail.

Prof Roger Sturmey, Professor of Reproductive Medicine, Hull York Medical School, University of Hull, said:

The work by Li and colleagues is an impressive technical achievement that has demonstrated the possibility that embryonic stem cells from a primate can be persuaded to form structures that mirror many features of early embryos.

Similar achievements have already been reported in other species, however this work assesses the primate embryo-like structures in detail and gives new insights into how the cell lineages families of cells that constitute the early embryo can be generated from stem cells.

Remarkably, when cultured in a laboatory, the embryo-like structures are able to replicate a number of key developmental features, most notably the formation of cells that resemble the primordial germ cells the cells that can produce gametes as well as the formation of a structure similar to the so-called primitive streak. When transferred into a recipient macaque uterus, these embryo-like structures were able to generate components of a pregnancy response, but were unable to develop, indicating that while these structures do share many features with competent embryos, there are still aspects of early development that differ between competent embryos and stem-cell derived models, preventing full development.

The work by Li and colleagues will offer important new tools in our understanding of the earliest stages of embryo development, but also highlight the need for guidance in this area, something that scientists in the UK are actively working on.

Prof Alfonso Martinez Arias, ICREA Senior Research Professor, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), said:

This is a timely study.

About half of human pregnancies fail during the proliferation of the zygote and the implantation of the blastocyst. Understanding the causes of this failure rate will impact human fertility and IVF success. In part to address this need, over the last few years, a number of Embryonic Stem (ES) cell models of early mammalian development have been created in the lab. Amidst these, mouse and human blastoids mimic mammalian blastocysts and as such can play an important role in understanding the process of implantation. Blastoids have been derived from mouse and human ES cells.

For these studies to go forward there is a need to develop a proper test for the function of the blastocyst: its implantation into the uterus. In the case of mouse blastoids this can be tested by implanting them into females. However, there is no such a test for human blastoids since, for obvious reasons, it is not possible to implant them into a human uterus. And yet there is a need to develop a system to study these structures in humans. Mouse reproductive biology and implantation are very different from human, which means that while an excellent system to find principles, the mouse is not useful for the specifics of this process; and this is what matters. It is this vacuum of a system to study human implantation and peri-implantation development that is addressed in the present study.

Following protocols established for human blastoids, macaque blastoids are made from nave stem cells and their potential is tested in two ways. One, by culturing them in vitro up to gastrulation stages and the other, by placing them in the uterus of a macaque foster mother. The idea behind this system is that it has reduced ethical barriers compared to human and therefore might provide an experimental system to test the potential of blastoids fully and, in the long term, to study infertility. The work is well conducted and the result is clear: although at the level of single cells macaque blastoids bear a strong resemblance to blastocysts, they do not behave as blastocysts. Although they implant and initiate gastrulation, they do not reach the end of this process. In vitro, blastoids cultured to form an epiblast and to undergo gastrulation, display progressive problems over time and, though they reach early stages of gastrulation, it is difficult to see in their data how faithful they are to an early gastrula. In one important experiment they implant some of these into female macaques and follow their progress with ultrasound. It appears as if they might perform well in the early stages of implantation, and the release of progesterone is a sign that something has gone well, but then, they disappear after about a week.

So, the important result of this work is that we are not close to generating blastoids that can be recognised as blastocysts by the mother. Definitely an important proof of principle but the lesson is that there is work to do.

An important difference between a blastoid and a blatocyst is their origin. The blastocyst in the egg, the blastoid in the ES cells. There might be elements in the oocyte that are important for the viability of the blastocysts and that will not be provided by the ES cells. Furthermore, if about 50% of conceptions fail at implantation, it is difficult to gauge whether the failure of the high level goal of the experiment (long term development in the womb) is due to defects in the blastoid system or whether the failure mirrors the natural situation; eight experimental subjects, the numbers of the experiment, are not sufficient to make a judgement. Only more experiments will decide and the one reported here, within well established ethical footprints, is definitely one to watch.

Dr Darius Widera, Associate Professor in Stem Cell Biology and Regenerative Medicine, University of Reading, said:

This is an interesting study that demonstrates the successful generation of embryo-like structures from monkey embryonic stem cells. These structures resembled natural early embryonic structures and could generate cell types of all three germ layers. Although similar studies have been conducted using human stem cells, this is the first report showing that (in this case, monkey) embryo-like structures can induce signs of pregnancy if transplanted into females. Therefore, the method could be used as a model of primate and human development and potentially provide new insights into certain factors that contribute to miscarriages in humans.

However, the study has some limitations. Only 3 out of 8 embryo-like structures were successfully implanted into female monkeys, and none of these persisted for more than one week. Thus, the structures do not have full developmental potential.

In addition, the ethical implications of embryonic stem cell research in monkeys are complex. Primates are intelligent, social animals with complex cognitive and emotional lives. Therefore, it is important to carefully consider both the potential benefits and the ethical impact of primate embryonic stem cell research.

Prof Robin Lovell-Badge FRS FMedSci, Group Leader, Francis Crick Institute, said:

The paper by Jie Li et al is another demonstration of the remarkable ability of pluripotent stem cells, in this case embryonic stem cells derived from early Macaque (non-human primate) embryos, to self-organise and begin a process of embryo formation in culture that mirrors that of normal Macaque embryos. However, the paper also shows that these stem cell-based embryo models are not entirely normal they could be implanted in female macaques, appear to initiate a pregnancy, but then fail soon after.

The authors were able to culture these stem cell-based embryo models, which they refer to as blastoids, through to gastrulation stages, equivalent to post-implantation embryos developing in a uterus, with good signs of development of all the main extraembryonic and embryonic tissues, where the latter included ectoderm, mesoderm and endoderm organised in a similar fashion to normal embryos. They could also demonstrate the presence of primordial germ cell-like cells and cells that are early progenitors of the blood system. These stages would be equivalent to those of human embryos at about 16 -18 days of development, beyond the 14 day limit (or the beginning of gastrulation) which is the maximum period normal human embryos are allowed to be cultured by law in the UK and some other countries.

It has been shown by others that human pluripotent stem cells can also be used to form blastoids, but to date such cultures have been stopped prior to gastrulation, but the paper by Li et al suggests that they could indeed be taken beyond this and provide valuable information about these early stages of human development that are otherwise very difficult to obtain. The data from the Macaque embryos and blastoid cultures may also help to understand aspects of human development, but without direct comparisons this will always be tentative, given how much mammalian embryos can vary at these stages.

These embryo models are referred to as integrated stem cell-based embryo models because they include extraembryonic tissues that normally give rise to the placenta and yolk sac that in a normal conceptus would permit implantation into the uterus and support the development of the embryo proper. So how much like a real embryo are these Macaque blastoids and could they implant and develop much further in a uterus? Although all the detailed comparisons presented in the paper of gene expression in the various cell types between normal Macaque embryos and the embryo models suggests that they can be very similar, the proportion of the blastoids reaching advanced stages was very low, indicating that most are not normal, and those that did still showed some differences. Moreover, while some could implant, begin to develop some complexity, and induce a typical response in the host uterus and lead to production of the typical pregnancy hormones, chorionic gonadotrophin and progesterone, the embryos all failed before gastrulation. This suggests that they failed to form fully functional extraembryonic tissues that could adequately support the embryo and that these could not give rise to a placenta, which would be essential for more complex development. It is likely that the same would be true for human integrated stem cell-based embryo models, although it would be unethical and illegal (in the UK) to attempt to implant these into a woman.

It seems likely that the culture methods for these integrated stem cell-based embryo models will be improved, and who knows it may eventually be possible to have them implant and develop normally, but the failure of this to happen as reported in this paper will give regulators some breathing space to develop appropriate rules for the culture of such human models, notably whether they can be taken beyond the equivalent of gastrulation stages, which would be of immense importance in helping to understand not just normal development of the human embryo, but what so often goes wrong and leads to embryo failure and congenital disorders.

Cynomolgus monkey embryo model captures gastrulation and early pregnancy by Jie Li et al. was published in Cell Stem Cell at 16:00 UK time on Thursday 6 April 2023.

DOI: 10.1016/j.stem.2023.03.009

Declared interests

Prof Magdalena Zernicka-Goetz: I have no conflict of interest to declare.

Prof Roger Sturmey: None.

Prof Alfonso Martinez Arias: I have no conflict of interests.

Dr Darius Widera: I have no conflict of interest to declare.

Prof Robin Lovell-Badge: I have no conflicts of interest to declare, except I do serve on the HFEAs Scientific and Clinical Advances Advisory Committee and I am a member of their Legislative Reform Advisory Group.

Continue reading here:
expert reaction to study looking at creating embryo-like structures ... - Science Media Centre

NANOG (Part 1): Its Role In Aging And Cancer – Forbes

eternal youth and the mythological island that NANOG protein was named after.Patrick Lynch, URL: https://www.irishcentral.com/roots/history/tir-na-nog-legend-eternal-youth

This is the first article in a series on the NANOG protein. Please see my companion series on klotho, another protein that may be involved in aging. You can read more about klotho in parts 1 and 2 of my series.

In Celtic mythology, Tr na ng is an island paradise and supernatural realm filled with everlasting youth, beauty, health, abundance, and joy. The inhabitants of Tr na ng consist of warriors and gods who are known for their poetry, music, and entertainment. By participating in the feast of Goibniu, the inhabitants of the island are granted immortality, giving Tr na ng its nickname The Land of Youth.

Now, studies report that a protein named after this Celtic taleNANOG may play a role in anti-aging and cancer prevention, but what is NANOG and why do researchers believe that it may prevent aging?

What is NANOG?

The key to NANOG and its biological function lies in our embryonic stem cells. Stem cells are a unique cell type, containing two characteristics that make them very powerful: pluripotency and the ability for self-renewal.

Pluripotency is the ability of stem cells to develop into many different tissues or cell types. While all embryonic stem cells are essentially the same basic cell, each stem cell has the potential to grow into nearly any tissue or cell type in the body. In other words, a single stem cell has multiple fates and depending on the environmental and chemical cues the stem cell is given, it can become anything from a brain cell to a muscle cell.

This becomes an especially important property when considering that stem cells have the ability to self-renew. Unlike many other cells, embryonic stem cells can simply divide to create multiples of themselves, allowing them to exist perpetually in the body so long as they can continue to self-renew.

What allows these stem cells to not only constantly regenerate, but to maintain their pluripotency? In other words, when new stem cells are created, what prevents them from spontaneously maturing into some form of adult cell?

Both pluripotency and self-renewal have been linked to a few, core transcription factors. Transcription factors are proteins in the body that control whether genes are turned on or off. Previous studies have found that the core transcription factors controlling stemness are Oct4, Sox2, Klf4, and NANOG.

How NANOG maintains pluripotency and self-renewal

An interesting aspect of NANOG is that it does not exist in adult cells. Instead, NANOG is only detected in stem cells that are still pluripotentthey have not begun to differentiate or develop into any particular cell type. Once a stem cell begins to differentiate, the NANOG gene is turned off and NANOG protein is no longer produced in the cell. Due to this observation, scientists suggest that NANOG may play a role in maintaining the pluripotency of stem cells, essentially preventing the stem cells from differentiating and maturing into adult cells.

There are three NANOG proteins that influence the pluripotency of human embryonic stem cells. These are Nanog1, Nanog2, and NanogP8. Researchers have found that when Nanog1 is abundant, it can prevent embryonic stem cells from differentiating. When the protein is scarce, embryonic stem cells tend to mature and differentiate into other cell types, losing their pluripotency.

NanogP8 is similar to Nanog1 except that it is mainly found in cancer cells, suggesting that NanogP8 may have larger anti-cancer properties than anti-aging properties.

How exactly could NANOG prevent stem cells from differentiating? While it is currently unclear what the biological mechanisms of NANOG are, two proteins that might offer a clue are leukemia inhibitory factor and STAT3. Both leukemia inhibitory factor proteins and STAT3 are widely known to prevent the differentiation of stem cells.

Leukemia inhibitory factor plays an important role in a wide array of biological processes including the growth of leukemia cancer cells and inflammation. The protein works primarily by controlling the activity of other transcription factors and proteins including STAT3. Researchers have found that when leukemia inhibitory factor levels drop and STAT3 activity decreases, stem cells begin to differentiate.

Interestingly, more recent experiments have shown that when NANOG is deficient, stem cells also differentiate. This occurs even in the presence of STAT3 and leukemia inhibitory factor, suggesting that NANOG may help maintain the pluripotency of stem cells by controlling the production and release of leukemia inhibitory factor and STAT3.

Additional studies focus on how NANOG may interact with other core transcription factors like Oct4 to prevent the differentiation of stem cells and maintain pluripotency. Researchers have suggested that NANOG and Oct4 may work together to control certain genes and proteins related to the pluripotency of stem cells. Oct4 is a transcription factor that is critically involved in the self-renewal of embryonic stem cells. Studies have shown that NANOG and Oct4 exhibit very similar patterns of behavior and often regulate similar genes in the body. This has led to the suspicion that NANOG and Oct4 may play a combined role in maintaining the pluripotency and self-renewal of embryonic stem cells.

Conclusion: NANOG in aging and cancer

While the biological mechanisms of how NANOG maintains the pluripotency of stem cells are unclear, it is evident that this small protein has an unusual ability to determine whether or not cells mature into different cell types. In the next installments of this short series, I will detail some of the more recent studies on NANOG, how the protein may prevent cellular aging, and how it could play a role in minimizing the growth of cancerous tumors.

I am a scientist, businessman, author, and philanthropist. For nearly two decades, I was a professor at Harvard Medical School and Harvard School of Public Health where I founded two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology. I am perhaps most well known for my work on cancer, HIV/AIDS, genomics and, today, on COVID-19. My autobiography, My Lifelong Fight Against Disease, publishes this October. I am chair and president of ACCESS Health International, a nonprofit organization I founded that fosters innovative solutions to the greatest health challenges of our day. Each of my articles at Forbes.com will focus on a specific healthcare challenge and offer best practices and innovative solutions to overcome those challenges for the benefit of all.

See the original post:
NANOG (Part 1): Its Role In Aging And Cancer - Forbes

Regenerative Medicine Market Investments, Share and Revenue … – GlobeNewswire

Jersey City, NJ, April 12, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "GlobalRegenerative Medicine Market Size, Share & Trends Analysis Report By Product (Therapeutics, Primary cell-based therapeutics, Stem Cell & Progenitor Cell-based therapeutics), By Therapeutic Category (Dermatology, Musculoskeletal, Immunology & Inflammation, and Oncology)- Market Outlook And Industry Analysis 2031"

The global Regenerative Medicine market is estimated to reach over USD 183.08 billion by 2031, exhibiting a CAGR of 15.02% during the forecast period.

In recent year, it has been determined that regenerative therapies can uniquely change the underlying pathological processes. Trial-stage regenerative medicines offer promising treatments for particular chronic diseases with unmet medical needs. Novartis announced the release of T-ChargeTM in December 2021, a next-generation CAR-T platform that would be used for cutting-edge investigational CAR-T cell treatments.

Free PDF Report Brochure @https://www.insightaceanalytic.com/request-sample/1687

The development of gene-based treatment, which uses targeted DNA delivery as a drug to combat numerous illnesses, results from significant effects in molecular therapeutics. With the restoration of gene function, gene therapy holds great promise for treating cancer and type 1 and type 2 diabetes. Gene-based medicines treat patients with conditions such as cancer, oncology, infectious diseases, cardiovascular disorders, monogenic diseases, genetic disorders, ophthalmological indications, and central nervous system illnesses. These elements have helped the market for regenerative medicine expand.

Recent Developments:

In April 2022, Obecabatagene autoleucel, a CD19-directed autologous chimeric antigen receptor T therapy being investigated in the ongoing FELIX Phase 2 study of leukaemia, has been given the Regenerative Medicine Advanced Therapy designation by the U.S. Food and Drug Administration (FDA). This was announced by Autolus Therapeutics plc.

List of Prominent Players in the Regenerative Medicine Market:

Get Customized Report @https://www.insightaceanalytic.com/customisation/1687

Regenerative Medicine Market Report Scope:

Market Dynamics:

Drivers- The ability of adult stem cells to proliferate or self-renew forever and to develop all the cell kinds of the organ from which they originate has propelled research into these cells, with the potential to regenerate the complete organ from a few cells. No embryo must be destroyed in order to produce adult stem cells. Furthermore, medical research on stem cells has been thoroughly examined and attracted much attention. ExCellThera Inc. and Ossium Health recently announced a partnership to explore and advance opportunities to use adult stem cells from deceased donors from Ossium Health's first-ever bone marrow bank in combination with ExCellThera's ECT-001 cell expansion and rejuvenation technology. This collaboration will take place in April 2021. These kinds of developments are anticipated to accelerate market expansion.

Challenges:The market for regenerative medicine is projected to be hampered by a lack of information and moral considerations surrounding the usage of embryonic stem cells for research and development. Since cell therapy is a crucial component of regenerative medicine, it has a significant impact on the market growth rate. One of the leading market inhibitors may be the high cost of investment, which might be followed by problems with assay sensitivity, robustness, and reproducibility; the challenge of culture/propagation; and finally, the challenge of handling.

Regional Trends:Due to the presence of big players, the rapid advancement of technology, significant investments in stem cell and oncology research, and the presence of major players, North America is predicted to have the largest revenue share. The largest market in North America is the United States. In the U.S., numerous stem cell therapies are increasingly being used to treat a growing number of ailments like cancer and diabetes. According to the Heart Disease & Stroke Statistics Fact Sheet 2020, congenital heart abnormalities are predicted to affect at least 40,000 infants annually in the United States.

Enquiry Before Buying @https://www.insightaceanalytic.com/enquiry-before-buying/1687

Segmentation of Regenerative Medicine Market-

By Product-

By Therapeutic Category-

By Region-

North America-

Europe-

Asia-Pacific-

Latin America-

Middle East & Africa-

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/

Read the original here:
Regenerative Medicine Market Investments, Share and Revenue ... - GlobeNewswire

Stem Cell Therapy Market Size is Estimated to Increase USD 44.5 … – GlobeNewswire

New York, April 11, 2023 (GLOBE NEWSWIRE) -- Market.us research reveals that The global stem cell therapy market size was estimated at USD 11.1 billion in 2022 and is expected to reach around USD 44.5 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 15.3% during the forecast period 2022 to 2030. Stem cell therapy is used to transplant stem cells; in this therapy, stem cells are changed by chemotherapy. Stem cell therapy contains types like Hematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), Skin Stem Cells (SSCs), and Neural Stem Cells (NSCs). Chemotherapy act as an immune system to face disorders linked to blood or cancer, such as multiple myeloma, neuroblastoma, lymphoma, and leukemia. The cost of each stem cell therapy method can vary between 5,000$ and 50,000$.

Identify key trends, drivers, and challenges in the stem cell therapy market, which will help vendors improve their strategies to stay ahead of their competitors. View our PDF Sample Report - https://market.us/report/stem-cell-therapy-market/request-sample/

Key Takeaway:

The stem cell therapy market increased owing to a lot of investment in stem cell research, various clinical trials related to stem cell therapy, and an increasing number of cell therapy production facilities. Several cell therapy clinical trials were done during the epidemic due to the various benefits of stem cell therapies.

Factors affecting the growth of the Stem Cell Therapy industry?

There are several factors that can affect the growth of the neonatal intensive care respiratory devices industry. Some of these factors include:

Interested to Procure the Data? Inquire here at -https://market.us/report/stem-cell-therapy-market/#inquiry

Top Trends in Global Stem Cell Therapy Market

The global cancer load is increasing. Hence, cancer therapies must be updated with regional and national priorities. Breast, lung, cervical, colorectal, and thyroid cancers are common among women. However, lung cancer and prostate cancer are the more frequent among men which, acquired a share of 33% of male cancer.

A stem cell transplant is a treatment for cancer types such as leukemia, neuroblastoma, multiple myeloma, or lymphoma types. Autologous transplants are favored in the cases such as leukemia, testicular cancer, multiple myeloma, lymphomas, and neuroblastoma. Autologous and allogeneic stem cell transplants can both be used for cancer treatments.

Regional Analysis

North America dominated the market share of the global stem cell therapy market, with 35% of this market in 2022. The most recent advanced technologies, considerable governmental & private investment, and economic expansion help to benefits the market region. The presence of the latest research infrastructure, rising R&D efforts to form chronic diseases therapeutic choices, and ordinary clinical trials review process for driving the market elements in the region. Key research organizations and market suppliers located in the United States receive large funding. Various projects in the region's pipeline are increasing consumer demand.

Due to an increase in the need for stem cell therapy and a rising prevalence of chronic and neurological diseases, Europe acquired the second-highest market share. The cell therapy in Asia-Pacific market growth is increasing at the highest growth rate because of its fast growth and several companies arrival in APAC. Moreover, the APAC region's increasing use of stem cell therapy and rising cancer dominance are projected to stimulate market expansion.

For more insights on the market share of various regions - Download a Sample Report

Scope of the Report

Market Drivers

The efficient treatment demand is increasing due to the rising chronic disease rate. In the COVID-19 epidemic, chronic diseases such as heart disease, cardiovascular disorder, cancer, neurological disorder, stroke, and respiratory illnesses place a big stress on society. Four of the ten adults have greater than two chronic diseases, and six of ten adults have at least one chronic disease. These show how diseases are dominating as well as how nicely they are managed. Clinical trials are expected to raise stem cell demand during the forecast period.

Market Restraints

Although research on stem cells is very promising for the medical sector, its expansion is restrained due to ethical issues by a regulatory bodies. The devastation of the human embryonic stem cell is the main issue that might have foiled the development of stem cell research.

Market Opportunities

The banking of stem cells need is rising as the number of chronic disorders and genetic abnormalities has increased. An increasing firm has stepped into the stem cell banking sector due to rising public awareness of stem cell therapy. To boost sales and market for stem cell therapy, adult stem cells, which are genetically programmed, are using embryonic stem cells called pluripotent stem cells.

Grow your profit margin with Market.us - Purchase Stem Cell Therapy Premium Market Report athttps://market.us/purchase-report/?report_id=12272

Report Segmentation of the Global Stem Cell Therapy Market

Cell Source Insight

The largest market share was dominated by adipose tissue with 34% market share in 2022. Because source of this cell is used in adipose tissue, which is a specialized connective tissue containing lipid-rich cells known as adipocytes. These adipocytes are mainly discovered in the skin and deposit among the muscles, intestines membrane folds, inside the intestines, near the heart, and other places. Moreover, the global stem cell therapy market share depends on cell source types segmented into IPSCs, neural, PPSCs, embryo/cord, adipose tissue, and bone marrow.

Type Insight

The global stem cell therapy market is growing because the largest market share was occupied by the allogenic segment, with a 74% market share in 2022, owing to its increasing incidence of cancer and other related disorders. The global stem cell therapy market share is based on the type segregated into allogenic stem cell therapy and autologous stem cell therapy. According to the WHO, children of ages 0 to 19 are diagnosed with almost 300K new cases of cancer annually. In 2022, there will be 21 million new cases of cancer, according to estimates. This puts a strain on the global healthcare system and increases the demand for cancer treatments that are efficient anywhere in the world.

Application Insight

The largest market share was dominated by the diabetes segment, with a 28% market share in 2022. Because 450 million people are infected by diabetes across the globe, from WHO report. Diabetes is normal in several countries for individuals of low and medium incomes. The global stem cell therapy market is based on applications segmented into cardiovascular, diabetes, cancer, musculoskeletal disorders, and gastrointestinal diseases. Furthermore, the diabetes segment, also called diabetes mellitus of metabolic disease that is infested when blood glucose levels are too high. Over time period, diabetes disorder can cause a lot of harm to the kidneys, eyes, blood vessels, heart, and eyes.

End User Insight

The largest market share was dominated by the hospitals & clinics segment, with a 28% market share in 2022 because of the rising occurrence of skin conditions like acne. The global stem cell therapy market is based on end-user types segmented into hospitals & clinics, academic & research centers, ambulatory surgical centers, and other end users.

Drivers and challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report: https://market.us/report/stem-cell-therapy-market/request-sample/

Market Segmentation

By Cell Source

By Type

By Application

By End User

By Geography

Competitive Landscape

With the presence of many local and regional players, the market for global stem cell therapy market is fragmented. Market players have intense competition from prominent key players, mainly those with big recognition of the brand and high networks for distribution. Companies have started various expansion strategies to gain a top spot in the market, such as partnerships and product launches.

The competitive landscape of the market has also been examined in this report. Some of the major players include

Recent Development of the Stem Cell Therapy Market

Browse More Related Reports:

About Us:

Market.US(Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicatedmarket research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us On LinkedIn Facebook Twitter

Our Blog:

Read more from the original source:
Stem Cell Therapy Market Size is Estimated to Increase USD 44.5 ... - GlobeNewswire

Ethical Considerations in Stem Cell Research and Therapy – PharmiWeb.com

Stem cell therapy is a rapidly developing field in modern medicine that holds great promise for the treatment of various diseases and injuries. Stem cells are unique cells that have the ability to develop into many different cell types in the body. They are also capable of renewing themselves through cell division, making them a valuable tool for repairing damaged tissues and organs.

Stem cell therapy involves the use of stem cells to treat or prevent diseases or conditions. These cells can be obtained from a variety of sources, including embryonic tissues, fetal tissues, and adult tissues. Once harvested, the stem cells can be manipulated in the laboratory to differentiate into specific cell types or tissues, depending on the needs of the patient.

According to The Insight Partners the stem cell therapy market is expected to grow from US$ 2,278.49 million in 2022 to US$ 6,206.89 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2022 to 2028.

Applications of Stem Cell Therapy

Stem cell therapy has the potential to revolutionize the treatment of a wide range of diseases and injuries. Some of the most promising applications of stem cell therapy include:

Heart disease: Stem cell therapy has been shown to be effective in repairing damaged heart tissue in patients with heart disease. Stem cells can be used to regenerate heart muscle cells, improve blood flow to the heart, and reduce the risk of heart failure.

Parkinson's disease: Stem cell therapy may offer a promising treatment option for patients with Parkinson's disease. Stem cells can be used to generate dopamine-producing neurons, which are essential for the control of movement and coordination.

Spinal cord injury: Stem cell therapy has the potential to repair damaged spinal cord tissue and restore function to paralyzed limbs. Stem cells can be used to replace lost nerve cells and promote the growth of new connections between the brain and the body.

Diabetes: Stem cell therapy may offer a cure for type 1 diabetes by generating insulin-producing cells that can replace those that have been destroyed by the disease.

Arthritis: Stem cell therapy may offer a new approach to the treatment of arthritis by regenerating damaged cartilage tissue and reducing inflammation.

Challenges and Controversies

Despite the promising potential of stem cell therapy, there are also significant challenges and controversies associated with its use. One of the most significant challenges is the ethical considerations surrounding the use of embryonic stem cells. Embryonic stem cells are derived from embryos that are a few days old and are often obtained from in vitro fertilization clinics. Some people object to the use of embryonic stem cells because it involves the destruction of the embryo.

Another challenge is the risk of tumor formation. Stem cells have the potential to differentiate into many different cell types, including cancer cells. If stem cells are not properly controlled and regulated, they can form tumors in the patient's body.

There are also concerns about the safety and effectiveness of stem cell therapies. Many stem cell therapies are still experimental and have not been fully tested in clinical trials. Some stem cell clinics offer unproven therapies that have not been adequately tested for safety or efficacy.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have taken steps to regulate stem cell therapies and ensure that they are safe and effective. The FDA has approved a limited number of stem cell therapies for specific indications, such as the use of bone marrow stem cells to treat certain types of cancer.

Trends in Stem Cell Therapy Industry

The field of stem cell therapy is rapidly evolving, and new developments are constantly emerging. Stem cell therapy has the potential to transform the treatment of a wide range of diseases and injuries, and as such, it is a rapidly growing industry. Here are some of the top trends in the stem cell therapy industry today:

Increased Focus on Personalized Medicine

One of the most significant trends in the stem cell therapy industry is the shift toward personalized medicine. Stem cell therapy has the potential to be tailored to the unique needs of each patient, based on their medical history, genetics, and other factors. As a result, many companies are now offering personalized stem cell therapies that are specifically designed for each individual patient.

Advancements in Stem Cell Manufacturing

Another trend in the stem cell therapy industry is the development of new manufacturing technologies that enable the production of large quantities of high-quality stem cells. Traditional methods of stem cell production, such as culturing cells in a laboratory dish, can be time-consuming and expensive. Newer methods, such as 3D printing and microfluidic devices, offer more efficient and cost-effective ways of producing stem cells.

Expansion of Stem Cell Therapy Applications

As research in stem cell therapy continues to advance, there are increasing numbers of potential applications for this technology. For example, stem cells are being explored for the treatment of conditions such as Alzheimer's disease, multiple sclerosis, and liver disease. The expansion of stem cell therapy applications is leading to increased investment in research and development, as well as greater commercialization of stem cell therapies.

Regulation and Standardization

With the increasing commercialization of stem cell therapies, there is growing concern about the need for regulation and standardization. Regulators and industry leaders are working to establish guidelines for the production, testing, and distribution of stem cell therapies. This will help to ensure that these therapies are safe, effective, and consistent.

Partnership and Collaboration

Collaboration between industry, academia, and government is crucial for the development and advancement of stem cell therapies. Many companies are forming partnerships with academic institutions and research organizations to advance the science of stem cell therapy. These collaborations are leading to greater innovation and faster progress in the field.

Gene Editing and Stem Cell Therapy

The emergence of gene editing technology, such as CRISPR-Cas9, is opening up new possibilities for the use of stem cell therapy. Gene editing allows researchers to modify the DNA of stem cells, potentially improving their safety and efficacy. This technology is also being explored for the development of new stem cell therapies that target specific genetic mutations that cause disease.

Conclusion

Stem cell therapy has the potential to revolutionize the treatment of many diseases and injuries, offering new hope to patients who have exhausted other treatment options. While there are still many challenges and controversies associated with the use of stem cells, ongoing research and clinical trials are helping to address these issues and move the field forward.

It is important for patients to be cautious when considering stem cell therapy and to consult with qualified medical professionals before undergoing any treatment. By working together, researchers, clinicians, and regulatory agencies can continue to develop and refine stem cell therapies and bring them to the patients who need them most.

Read this article:
Ethical Considerations in Stem Cell Research and Therapy - PharmiWeb.com